Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CGEM NASDAQ:DSGN NASDAQ:MGTX NASDAQ:NKTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGEMCullinan Therapeutics$15.69-2.9%$14.29$5.68▼$16.74$960.59M-0.09793,479 shs91,862 shsDSGNDesign Therapeutics$14.01-3.7%$12.09$3.31▼$17.25$868.78M1.73345,738 shs68,963 shsMGTXMeiraGTx$9.73-2.2%$8.83$4.82▼$11.85$897.47M1.23593,439 shs79,687 shsNKTXNkarta$2.74-2.7%$2.58$1.63▼$3.65$193.52M0.88814,807 shs142,373 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGEMCullinan Therapeutics-1.10%+9.71%+12.54%+39.34%+126.51%DSGNDesign Therapeutics-6.91%+3.12%+15.03%+44.39%+352.96%MGTXMeiraGTx-0.20%+2.79%-11.87%+33.56%+114.44%NKTXNkarta-8.17%-10.79%+22.71%+42.64%+50.27%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGEMCullinan Therapeutics$15.69-2.9%$14.29$5.68▼$16.74$960.59M-0.09793,479 shs91,862 shsDSGNDesign Therapeutics$14.01-3.7%$12.09$3.31▼$17.25$868.78M1.73345,738 shs68,963 shsMGTXMeiraGTx$9.73-2.2%$8.83$4.82▼$11.85$897.47M1.23593,439 shs79,687 shsNKTXNkarta$2.74-2.7%$2.58$1.63▼$3.65$193.52M0.88814,807 shs142,373 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGEMCullinan Therapeutics-1.10%+9.71%+12.54%+39.34%+126.51%DSGNDesign Therapeutics-6.91%+3.12%+15.03%+44.39%+352.96%MGTXMeiraGTx-0.20%+2.79%-11.87%+33.56%+114.44%NKTXNkarta-8.17%-10.79%+22.71%+42.64%+50.27%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCGEMCullinan Therapeutics 2.67Moderate Buy$30.7596.05% UpsideDSGNDesign Therapeutics 2.88Moderate Buy$16.5017.78% UpsideMGTXMeiraGTx 2.75Moderate Buy$25.83165.50% UpsideNKTXNkarta 2.50Moderate Buy$11.33314.38% UpsideCurrent Analyst Ratings BreakdownLatest NKTX, MGTX, CGEM, and DSGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2026MGTXMeiraGTx Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$24.00 ➝ $25.005/13/2026NKTXNkarta Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$11.005/12/2026DSGNDesign Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight5/8/2026CGEMCullinan Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$36.00 ➝ $37.005/4/2026DSGNDesign Therapeutics OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$18.00 ➝ $21.005/4/2026CGEMCullinan Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$38.004/29/2026DSGNDesign Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$20.004/28/2026CGEMCullinan Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$38.004/28/2026CGEMCullinan Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$27.00 ➝ $30.004/22/2026MGTXMeiraGTx Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$26.00 ➝ $30.004/21/2026MGTXMeiraGTx Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 5/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCGEMCullinan TherapeuticsN/AN/AN/AN/A$5.96 per shareN/ADSGNDesign TherapeuticsN/AN/AN/AN/A$3.49 per shareN/AMGTXMeiraGTx$81.39M11.07N/AN/A($0.07) per share-139.00NKTXNkartaN/AN/AN/AN/A$4.00 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCGEMCullinan Therapeutics-$219.88M-$3.36N/AN/AN/AN/A-51.45%-47.64%N/ADSGNDesign Therapeutics-$69.79M-$1.20N/AN/AN/AN/A-33.07%-31.29%N/AMGTXMeiraGTx-$114.20M-$1.42N/AN/AN/A-140.31%-1,065.47%-53.33%N/ANKTXNkarta-$104.08M-$1.34N/AN/AN/AN/A-30.90%-24.20%N/ALatest NKTX, MGTX, CGEM, and DSGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026MGTXMeiraGTx-$0.58-$0.57+$0.01-$0.57$17.00 million$0.29 million5/12/2026Q1 2026NKTXNkarta-$0.39-$0.37+$0.02-$0.37N/AN/A5/7/2026Q1 2026CGEMCullinan Therapeutics-$0.8359-$0.75+$0.0859-$0.75$3.67 millionN/A4/28/2026Q1 2026DSGNDesign Therapeutics-$0.36-$0.29+$0.07-$0.29N/AN/A3/26/2026Q4 2025MGTXMeiraGTx-$0.60$0.19+$0.79$0.19$3.87 million$75.36 million3/25/2026Q4 2025NKTXNkarta-$0.32-$0.37-$0.05-$0.37N/AN/A3/10/2026Q4 2025CGEMCullinan Therapeutics-$0.80-$0.77+$0.03-$0.77$5.56 millionN/A3/9/2026Q4 2025DSGNDesign Therapeutics-$0.38-$0.27+$0.11-$0.27N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCGEMCullinan TherapeuticsN/AN/AN/AN/AN/ADSGNDesign TherapeuticsN/AN/AN/AN/AN/AMGTXMeiraGTxN/AN/AN/AN/AN/ANKTXNkartaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCGEMCullinan TherapeuticsN/A10.2810.28DSGNDesign TherapeuticsN/A22.2822.28MGTXMeiraGTxN/A0.750.75NKTXNkartaN/A12.9612.69Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCGEMCullinan Therapeutics86.31%DSGNDesign Therapeutics56.64%MGTXMeiraGTx67.48%NKTXNkarta80.54%Insider OwnershipCompanyInsider OwnershipCGEMCullinan Therapeutics8.60%DSGNDesign Therapeutics23.50%MGTXMeiraGTx7.50%NKTXNkarta8.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCGEMCullinan Therapeutics3061.46 million56.17 millionOptionableDSGNDesign Therapeutics4062.46 million47.78 millionOptionableMGTXMeiraGTx30092.57 million85.63 millionOptionableNKTXNkarta14071.54 million65.30 millionOptionableNKTX, MGTX, CGEM, and DSGN HeadlinesRecent News About These CompaniesHere's Why We're Not Too Worried About Nkarta's (NASDAQ:NKTX) Cash Burn SituationMay 14 at 6:08 PM | finance.yahoo.comNkarta's (NKTX) "Buy" Rating Reaffirmed at Needham & Company LLCMay 14 at 3:55 AM | americanbankingnews.comNkarta Reports First Quarter 2026 Financial Results and Corporate HighlightsMay 12 at 4:01 PM | globenewswire.comNkarta (NKTX) Projected to Post Quarterly Earnings on WednesdayMay 11, 2026 | americanbankingnews.comNkarta (NKTX) Projected to Post Earnings on WednesdayMay 6, 2026 | marketbeat.comNkarta, Inc. (NASDAQ:NKTX) Given Average Rating of "Hold" by AnalystsMay 1, 2026 | marketbeat.comNkarta (NASDAQ:NKTX) Stock Price Down 3.1% - Here's WhyApril 28, 2026 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Nkarta (NKTX), QT Imaging Holdings (QTI) and Cardiff Oncology (CRDF)April 23, 2026 | theglobeandmail.comNKTX Stock Up on Upbeat Regulatory Update on Lead Autoimmune ProgramApril 17, 2026 | zacks.comNkarta rises on FDA agreement for amended trial protocolApril 16, 2026 | msn.comNkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology CentersApril 15, 2026 | globenewswire.comNkarta to Participate in Needham Virtual Healthcare ConferenceApril 9, 2026 | globenewswire.comNkarta Launches $100 Million At-the-Market Stock OfferingMarch 26, 2026 | tipranks.comNkarta Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate HighlightsMarch 25, 2026 | globenewswire.comNkarta to Participate in March Investor ConferencesFebruary 27, 2026 | globenewswire.comInsider Selling: Nkarta (NASDAQ:NKTX) President Sells 5,649 Shares of StockJanuary 21, 2026 | insidertrades.comWe Think Nkarta (NASDAQ:NKTX) Needs To Drive Business Growth CarefullyDecember 4, 2025 | finance.yahoo.comNkarta to Participate in Evercore Healthcare ConferenceDecember 2, 2025 | globenewswire.comNkarta: Pushing Deeper And Deeper Into A Discount Vs. Their Holdings, For No Real ReasonNovember 22, 2025 | seekingalpha.comAnalysts Offer Insights on Healthcare Companies: Rallybio (RLYB) and Nkarta (NKTX)November 11, 2025 | theglobeandmail.comNkarta price target lowered to $11 from $12 at StifelNovember 11, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNKTX, MGTX, CGEM, and DSGN Company DescriptionsCullinan Therapeutics NASDAQ:CGEM$15.68 -0.47 (-2.88%) As of 10:41 AM Eastern This is a fair market value price provided by Massive. Learn more.Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.Design Therapeutics NASDAQ:DSGN$14.01 -0.53 (-3.65%) As of 10:42 AM Eastern This is a fair market value price provided by Massive. Learn more.Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.MeiraGTx NASDAQ:MGTX$9.73 -0.22 (-2.21%) As of 10:42 AM Eastern This is a fair market value price provided by Massive. Learn more.MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.Nkarta NASDAQ:NKTX$2.74 -0.08 (-2.67%) As of 10:42 AM Eastern This is a fair market value price provided by Massive. Learn more.Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas YETI Rallies After Earnings Beat and Raised Outlook Cisco’s Vertical Rally May Still Be in the Early Innings Be Ready: 3 Upcoming Catalysts Could Drive Oracle to Record Highs Dividend Growth or High Yield: The Income Investor's Bet Nebius Upside Expands as AI Feedback Loop Intensifies 2 Ways to Play the Big Pharma Patent Cliff Oklo Stock Could Be Ready for Another Massive Run Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
